- Patent Title: Ruxolitinib formulation for reduction of itch in atopic dermatitis
-
Application No.: US17705624Application Date: 2022-03-28
-
Publication No.: US11590137B2Publication Date: 2023-02-28
- Inventor: Michael Kuligowski , Kang Sun , Michael Howell , May Grace E. Venturanza , Jim Lee
- Applicant: Incyte Corporation
- Applicant Address: US DE Wilmington
- Assignee: Incyte Corporation
- Current Assignee: Incyte Corporation
- Current Assignee Address: US DE Wilmington
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K9/06 ; A61P17/00 ; A61K9/107 ; A61K9/00 ; A61K31/4155
Abstract:
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Public/Granted literature
- US20220280518A1 RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITIS Public/Granted day:2022-09-08
Information query
IPC分类:
